Skip to search formSkip to main contentSkip to account menu

L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein

Known as: L19-IL2 
An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB…
PurposeTo analyze the impact of TNFα or IL2 on human lymphocytes in vitro and the anti-tumor and immune-modifying effects of L19… 
2016
2016
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients.
9064 Background:L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format directed… 
2016
2016
IL2 based immunotherapies: towards a personalized and curative antitumor response
In his commentary, Claus Garbe described our study on the combination of radiotherapy (RT) and the immunocytokine L19-IL2 in the… 
2015
2015
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
Recently, we have shown that radiotherapy (RT) combined with L19-IL2 can induce a long-lasting antitumor effect, dependent on ED… 
2015
2015
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
2014
2014
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.
9041^ Background: In previous studies, intralesional injection with interleukin-2 (IL2) showed efficacy for the intratumoral… 
2014
2014
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.
TPS9103^ Background: Preclinical studies in three different murine models of subcutaneous tumors have shown that a single… 
2011
2011
A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
2011
2011
A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma.
2531 Background: L19-IL2 is a tumor-targeting immunocytokine composed of an antibody fragment specific to the EDB domain of… 
2008
2008
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma
16032 Background: L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)